image
Fate Therapeutics, Inc. FATE
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 1.12
-0.884 %
$ 128 M
Market Cap
-0.75
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one FATE stock under the worst case scenario is HIDDEN Compared to the current market price of 1.12 USD, Fate Therapeutics, Inc. is HIDDEN

FATE Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one FATE stock under the base case scenario is HIDDEN Compared to the current market price of 1.12 USD, Fate Therapeutics, Inc. is HIDDEN

FATE Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one FATE stock under the best case scenario is HIDDEN Compared to the current market price of 1.12 USD, Fate Therapeutics, Inc. is HIDDEN

FATE Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart FATE

image
1M -43%
6M -61%
1Y -179%
3Y -2579%
5Y -3048%
All
$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
13.6 M REVENUE
-78.55%
Growth Rates
1Year -78.55%
3Years -37.51%
5Years 5.00%
7Years 18.70%
10Years 0.00%
-210 M OPERATING INCOME
-10.37%
Growth Rates
1Year -10.37%
3Years 1.04%
5Years -15.86%
7Years -25.82%
10Years -23.78%
-186 M NET INCOME
-15.74%
Growth Rates
1Year -15.74%
3Years 4.25%
5Years -13.67%
7Years -23.32%
10Years -21.82%
-123 M OPERATING CASH FLOW
7.10%
Growth Rates
1Year 7.10%
3Years 8.97%
5Years -8.12%
7Years -18.75%
10Years -18.55%
12.2 M INVESTING CASH FLOW
-89.16%
Growth Rates
1Year -89.16%
3Years 26.78%
5Years 15.75%
7Years 18.07%
10Years 31.83%
99.9 M FINANCING CASH FLOW
117420.00%
Growth Rates
1Year 117420.00%
3Years -39.59%
5Years -7.80%
7Years 11.22%
10Years 18.45%
1.63 M REVENUE
-12.42%
Growth Rates
1Year -78.55%
3Years -37.51%
5Years 5.00%
7Years 18.70%
10Years 0.00%
-41.3 M OPERATING INCOME
33.15%
Growth Rates
1Year -10.37%
3Years 1.04%
5Years -15.86%
7Years -25.82%
10Years -23.78%
-37.6 M NET INCOME
27.86%
Growth Rates
1Year -15.74%
3Years 4.25%
5Years -13.67%
7Years -23.32%
10Years -21.82%
-33.8 M OPERATING CASH FLOW
-21.62%
Growth Rates
1Year 7.10%
3Years 8.97%
5Years -8.12%
7Years -18.75%
10Years -18.55%
42.7 M INVESTING CASH FLOW
87.03%
Growth Rates
1Year -89.16%
3Years 26.78%
5Years 15.75%
7Years 18.07%
10Years 31.83%
0 FINANCING CASH FLOW
0.00%
Growth Rates
1Year 117420.00%
3Years -39.59%
5Years -7.80%
7Years 11.22%
10Years 18.45%
Balance Sheet Fate Therapeutics, Inc.
image
Current Assets 292 M
Cash & Short-Term Investments 279 M
Receivables 3.54 M
Other Current Assets 9.3 M
Non-Current Assets 149 M
Long-Term Investments 27.7 M
PP&E 111 M
Other Non-Current Assets 10.2 M
63.32 %6.28 %25.16 %Total Assets$440.7m
Current Liabilities 38.5 M
Accounts Payable 9.36 M
Short-Term Debt 7.42 M
Other Current Liabilities 21.7 M
Non-Current Liabilities 83.4 M
Long-Term Debt 77.8 M
Other Non-Current Liabilities 5.6 M
7.68 %6.08 %17.83 %63.83 %4.59 %Total Liabilities$122.0m
EFFICIENCY
Earnings Waterfall Fate Therapeutics, Inc.
image
Revenue 13.6 M
Cost Of Revenue 0
Gross Profit 13.6 M
Operating Expenses 224 M
Operating Income -210 M
Other Expenses -24 M
Net Income -186 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)14m014m(224m)(210m)24m(186m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
Averages
1Year 100.00%
3Years 10.40%
5Years -35.78%
7Years -283.24%
10Years -393.73%
-1542.63% OPERATING MARGIN
-1542.63%
Averages
1Year -1542.63%
3Years -720.91%
5Years -591.75%
7Years -759.62%
10Years -821.22%
-1366.46% NET MARGIN
-1366.46%
Averages
1Year -1366.46%
3Years -628.20%
5Years -559.16%
7Years -730.81%
10Years -815.56%
-58.44% ROE
-58.44%
Averages
1Year -58.44%
3Years -51.61%
5Years -45.90%
7Years -44.42%
10Years -49.12%
-42.27% ROA
-42.27%
Averages
1Year -42.27%
3Years -36.74%
5Years -31.99%
7Years -31.93%
10Years -34.37%
-51.34% ROIC
-51.34%
Averages
1Year -51.34%
3Years -45.97%
5Years -37.17%
7Years -36.96%
10Years -38.37%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Fate Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -186 M
Depreciation & Amortization 19 M
Capital Expenditures -730 K
Stock-Based Compensation 41.5 M
Change in Working Capital -1.96 M
Others 4.89 M
Free Cash Flow -124 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Fate Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for FATE of $4.33 , with forecasts ranging from a low of $3 to a high of $5 .
FATE Lowest Price Target Wall Street Target
3 USD 167.86%
FATE Average Price Target Wall Street Target
4.33 USD 286.90%
FATE Highest Price Target Wall Street Target
5 USD 346.43%
Price
Max Price Target
Min Price Target
Average Price Target
666655554444333322221111Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Fate Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
31.4 K USD 3
6-9 MONTHS
574 K USD 1
9-12 MONTHS
2.68 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
669 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company's common stock at an exercise price per share of $1.12, which was the closing price per share of the Company's common stock as reported by NASDAQ on July 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 37,900 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. globenewswire.com - 6 days ago
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? zacks.com - 3 weeks ago
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in SLE (DORIS) globenewswire.com - 4 weeks ago
Top Cancer Stocks to Supercharge Your 2025 Portfolio Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies. zacks.com - 4 weeks ago
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. globenewswire.com - 1 month ago
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) globenewswire.com - 1 month ago
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus. zacks.com - 1 month ago
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates Fate Therapeutics (FATE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.47 per share a year ago. zacks.com - 1 month ago
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June globenewswire.com - 1 month ago
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector I've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm. Revisiting FATE after a year, I aim to determine if the market's lack of interest is justified or a broader cell therapy sector issue. The article explores FATE's pipeline updates, financial overview, and strengths and risks to provide a comprehensive investment thesis. seekingalpha.com - 2 months ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2025 the Company granted restricted stock units (RSUs) representing 30,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. globenewswire.com - 2 months ago
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications globenewswire.com - 2 months ago
8. Profile Summary

Fate Therapeutics, Inc. FATE

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 128 M
Dividend Yield 0.00%
Description Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Contact 12278 Scripps Summit Drive, San Diego, CA, 92131 https://www.fatetherapeutics.com
IPO Date Oct. 1, 2013
Employees 181
Officers Mr. Andrew Henry Senior Vice President of Clinical Operations Dr. Tunde Babalola Senior Vice President of Technical Operations Dr. Bahram Valamehr M.B.A., Ph.D. President, Chief Executive Officer & Director Mr. Victor Hong Vice President of Corporate Development & Finance Ms. Jessica Francis Vice President Of Human Resources & Operations Ms. Cindy R. Tahl J.D. Chief Legal & Compliance Officer and Corporate Secretary Dr. Yu Cai Head of Intellectual Property & Assistant General Counsel Ms. Kate Duvall Corporate Controller